Olivia Trummer1, Uwe Langsenlehner2, Sabine Krenn-Pilko3, Thomas R Pieber1, Barbara Obermayer-Pietsch1, Armin Gerger4, Wilfried Renner5, Tanja Langsenlehner3. 1. Division of Endocrinology and Metabolism, Department of Internal Medicine, Medical University of Graz, Graz, Austria. 2. Division of Internal Medicine, GKK Outpatient Department, Graz, Austria. 3. Department of Therapeutic Radiology and Oncology, Medical University of Graz, Graz, Austria. 4. Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria. 5. Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, 8036, Graz, Austria. wilfried.renner@medunigraz.at.
Abstract
PURPOSE:Decreased vitamin D levels have been associated with prostate cancer, but it is unclear whether this association is causal. A functional single-nucleotide polymorphism (SNP) in the group-specific component (GC) gene (T > G, rs2282679) has been associated with 25-hydroxy (25-OH) vitamin D and 1.25 dihydroxy (1.25-OH2) vitamin D levels. METHODS: To examine the hypothesized inverse relationship between vitamin D status and prostate cancer, we studied the association between this SNP and prostate cancer outcome in the prospective PROCAGENE study comprising 702 prostate cancer patients with a median follow-up of 82 months. RESULTS: GC rs2282679 genotypes were not associated with biochemical recurrence [hazard ratios (HR) 0.91, 95 % confidence interval (CI) 0.73-1.12; p = 0.36], development of metastases (HR 1.20, 95 % CI 0.88-1.63; p = 0.25) or overall survival (HR 1.10; 95 % CI 0.84-1.43; p = 0.50). CONCLUSIONS: A causal role of vitamin D status, as reflected by GC rs2282679 genotype, in disease progression and mortality in prostate cancer patients is unlikely.
RCT Entities:
PURPOSE: Decreased vitamin D levels have been associated with prostate cancer, but it is unclear whether this association is causal. A functional single-nucleotide polymorphism (SNP) in the group-specific component (GC) gene (T > G, rs2282679) has been associated with 25-hydroxy (25-OH) vitamin D and 1.25 dihydroxy (1.25-OH2)vitamin D levels. METHODS: To examine the hypothesized inverse relationship between vitamin D status and prostate cancer, we studied the association between this SNP and prostate cancer outcome in the prospective PROCAGENE study comprising 702 prostate cancerpatients with a median follow-up of 82 months. RESULTS: GC rs2282679 genotypes were not associated with biochemical recurrence [hazard ratios (HR) 0.91, 95 % confidence interval (CI) 0.73-1.12; p = 0.36], development of metastases (HR 1.20, 95 % CI 0.88-1.63; p = 0.25) or overall survival (HR 1.10; 95 % CI 0.84-1.43; p = 0.50). CONCLUSIONS: A causal role of vitamin D status, as reflected by GC rs2282679 genotype, in disease progression and mortality in prostate cancerpatients is unlikely.
Authors: James Mohler; Robert R Bahnson; Barry Boston; J Erik Busby; Anthony D'Amico; James A Eastham; Charles A Enke; Daniel George; Eric Mark Horwitz; Robert P Huben; Philip Kantoff; Mark Kawachi; Michael Kuettel; Paul H Lange; Gary Macvicar; Elizabeth R Plimack; Julio M Pow-Sang; Mack Roach; Eric Rohren; Bruce J Roth; Dennis C Shrieve; Matthew R Smith; Sandy Srinivas; Przemyslaw Twardowski; Patrick C Walsh Journal: J Natl Compr Canc Netw Date: 2010-02 Impact factor: 11.908
Authors: Michel Bolla; Theodorus M de Reijke; Geertjan Van Tienhoven; Alphonsus C M Van den Bergh; Jorg Oddens; Philip M P Poortmans; Eliahu Gez; Paul Kil; Atif Akdas; Guy Soete; Oleg Kariakine; Elsbietha M van der Steen-Banasik; Elena Musat; Marianne Piérart; Murielle E Mauer; Laurence Collette Journal: N Engl J Med Date: 2009-06-11 Impact factor: 91.245
Authors: Evropi Theodoratou; Tom Palmer; Lina Zgaga; Susan M Farrington; Paul McKeigue; Farhat V N Din; Albert Tenesa; George Davey-Smith; Malcolm G Dunlop; Harry Campbell Journal: PLoS One Date: 2012-06-06 Impact factor: 3.240
Authors: John R Davies; Sinead Field; Juliette Randerson-Moor; Mark Harland; Rajiv Kumar; Gabriella M Anic; Eduardo Nagore; Johan Hansson; Veronica Höiom; Göran Jönsson; Nelleke A Gruis; Jong Y Park; Jian Guan; P Sivaramakrishna Rachakonda; Judith Wendt; Dace Pjanova; Susana Puig; Dirk Schadendorf; Ichiro Okamoto; Håkan Olsson; Paul Affleck; Zaida García-Casado; Joan Anton Puig-Butille; Alexander J Stratigos; Elizabeth Kodela; Simona Donina; Antje Sucker; Ismail Hosen; Kathleen M Egan; Jennifer H Barrett; Remco van Doorn; D Timothy Bishop; Julia Newton-Bishop Journal: Pigment Cell Melanoma Res Date: 2013-12-11 Impact factor: 4.693
Authors: Rebecca Gilbert; Carolina Bonilla; Chris Metcalfe; Sarah Lewis; David M Evans; William D Fraser; John P Kemp; Jenny L Donovan; Freddie C Hamdy; David E Neal; J Athene Lane; George Davey Smith; Mark Lathrop; Richard M Martin Journal: Cancer Causes Control Date: 2014-12-09 Impact factor: 2.506
Authors: Roger Bouillon; Claudio Marcocci; Geert Carmeliet; Daniel Bikle; John H White; Bess Dawson-Hughes; Paul Lips; Craig F Munns; Marise Lazaretti-Castro; Andrea Giustina; John Bilezikian Journal: Endocr Rev Date: 2019-08-01 Impact factor: 19.871
Authors: P G Vaughan-Shaw; F O'Sullivan; S M Farrington; E Theodoratou; H Campbell; M G Dunlop; L Zgaga Journal: Br J Cancer Date: 2017-03-16 Impact factor: 7.640